Get started
Author

Regina García‐Delgado

Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
2017 · Moshe Mittelman, Uwe Platzbecker, et al. · The Lancet Haematology · 104
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
2014 · Regina García-Delgado, Dunia de Miguel, et al. · Leukemia Research · 53
BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis
2022 · Srdan Verstovsek, Haifa Kathrin Al-Ali, et al. · Future Oncology · 40
Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis
2016 · Juan‐Carlos Hernández‐Boluda, Juan‐Gonzalo Correa, et al. · European Journal Of Haematology · 40
Effect of CPAP on Oxidative Stress and Circulating Progenitor Cell Levels in Sleep Patients With Apnea-Hypopnea Syndrome
2011 · Mora Murri, Regina García-Delgado, et al. · Respiratory Care · 30
PDF
Continuous Positive Airway Pressure Therapy Reduces Oxidative Stress Markers and Blood Pressure in Sleep Apnea–Hypopnea Syndrome Patients
2011 · Mora Murri, Regina García-Delgado, et al. · Biological Trace Element Research · 17
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
2022 · Ana Triguero, Alexandra Pedraza, et al. · Annals of Hematology · 12
An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib
2020 · John Mascarenhas, Alessandro M. Vannucchi, et al. · Blood · 10
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
2019 · Jason Gotlib, Nashat Gabrail, et al. · Blood · 10
An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor
2019 · Regina Garcia-Delgado, Donal P. McLornan, et al. · Blood · 7
Enhanced Facial Rejuvenation: Biostimulatory Effects of Hylan Gel Dermal Filler DX on Collagen Synthesis and Tissue Regeneration
2025 · Rodolfo M. Ortiz-Flores, Alejandro Escamilla-Sanchez, et al. · Aesthetic Plastic Surgery · 5
PDF
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
2022 · María García-Fortes, Juan C. Hernández-Boluda, et al. · Cancers · 4
Low-Risk Polycythemia Vera Treated with Phlebotomies: Clinical Characteristics, Hematologic Control and Complications in 358 Patients from the Spanish Registry of Polycythemia Vera
2021 · Ana Triguero, Alexandra Pedraza, et al. · Blood · 4
Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis
2025 · Prithviraj Bose, Jean-Christophe Ianotto, et al. · Blood · 2
PDF
Translational Insights into Interferon Alpha’s Effects on Immunomolecular Dynamics in Philadelphia-Negative Myeloproliferative Neoplasms
2025 · Regina García-Delgado, Elena Luque-Lupiáñez, et al. · Cancers · 2
PDF
Impact of iron chelation therapy on mitochondrial function, vascular integrity and inflammation in transfusion-dependent myelodysplastic syndromes
2025 · Regina García-Delgado, Gloria Moreno-Carrasco, et al. · Frontiers in Immunology · 1
PDF
Correction: García-Delgado et al. Translational Insights into Interferon Alpha’s Effects on Immunomolecular Dynamics in Philadelphia-Negative Myeloproliferative Neoplasms. Cancers 2025, 17, 2273
2026 · Regina García-Delgado, Elena Luque-Lupiáñez, et al. · Cancers
Dissociated Humoral and Cellular Immune Responses to Recombinant Zoster Vaccine in Myeloproliferative Neoplasms Under JAK Inhibition: A Pilot Study
2026 · Julio Torres-González, Blanca O’Donnell-Cortés, et al. · International Journal of Molecular Sciences
PDF
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera
2022 · Ana Triguero, Alexandra Pedraza, et al. · Annals of Hematology
An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis
2020 · Peter AW te Boekhorst, Alexandre Theocharides, et al. · Blood
The effect of Desferasirox in expression of Adhesion molecules in Neutrophils and Monocytes, in the Platelets Activacion and in the Atherothrombosis in Patients with Mielodisplastic Syndrome (MDS) and iron Overload.
2009 · Isabel Caparros, Regina Garcia-Delgado, et al. · Blood
Works count: 21
Citation count: 341
H-index: 9
I10-index: 9
Year
Topic
Type